Demographics and clinical characteristics of JHU and University of Minnesota prospective cohorts
| Variable . | Total cohort . | Black . | White . | Other . |
|---|---|---|---|---|
| Total individuals, n | 97 | 60 | 36 | 1 |
| Total episodes, n | 188 | 127 | 59 | 2 |
| Total number of RTX-treated iTTP episodes per patient, median (IQR) | 1 (1-2) | 1 (1-3) | 1 (1-2) | 2 (2-2) |
| Age at episode, median (IQR), y | 45 (34.5-55.5) | 45 (36-55) | 44 (30-60) | 41 (41-41) |
| Female sex, n (%) | 71 (73.2) | 43 (71.7) | 27 (75.0) | 1 (100) |
| De novo episodes | 51 (27.1) | 32 (25.2) | 18 (30.5) | 1 (50) |
| Relapse episodes | 137 (72.9) | 95 (74.8) | 41 (69.5) | 1 (50) |
| Any ADAMTS13 relapse | 18 (18.6) | 15 (25.0) | 13 (36.1) | 0 (0.0) |
| Any preemptive RTX received | 19 (19.5) | 9 (15.0) | 10 (27.8) | 0 (0.0) |
| Total follow-up time, median (IQR), y | 2.6 (0.7-5.9) | 3.0 (0.7-6.0) | 1.7 (0.7-6.0) | 0.9 (0.9-0.9) |
| Variable . | Total cohort . | Black . | White . | Other . |
|---|---|---|---|---|
| Total individuals, n | 97 | 60 | 36 | 1 |
| Total episodes, n | 188 | 127 | 59 | 2 |
| Total number of RTX-treated iTTP episodes per patient, median (IQR) | 1 (1-2) | 1 (1-3) | 1 (1-2) | 2 (2-2) |
| Age at episode, median (IQR), y | 45 (34.5-55.5) | 45 (36-55) | 44 (30-60) | 41 (41-41) |
| Female sex, n (%) | 71 (73.2) | 43 (71.7) | 27 (75.0) | 1 (100) |
| De novo episodes | 51 (27.1) | 32 (25.2) | 18 (30.5) | 1 (50) |
| Relapse episodes | 137 (72.9) | 95 (74.8) | 41 (69.5) | 1 (50) |
| Any ADAMTS13 relapse | 18 (18.6) | 15 (25.0) | 13 (36.1) | 0 (0.0) |
| Any preemptive RTX received | 19 (19.5) | 9 (15.0) | 10 (27.8) | 0 (0.0) |
| Total follow-up time, median (IQR), y | 2.6 (0.7-5.9) | 3.0 (0.7-6.0) | 1.7 (0.7-6.0) | 0.9 (0.9-0.9) |
RTX, rituximab.